WINNIPEG, MANITOBA--(Marketwire - April 16, 2008) - Medicure Inc. (TSX: MPH)(AMEX: MCU), a cardiovascular-focused biopharmaceutical company, today announced that the positive results from the Phase II MATCHED study, which evaluated the combination of MC-1 and lisinopril in patients with coexisting type II diabetes and hypertension, will be presented today at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Annual Conference 2008 in Atlanta, GA.
